The study describes two syndromes, which combine clinical manifestations and differential cerebrospinal fluid profiles, which determine a different prognosis in patients.
The biomarker candidate is a fragment of a neuronal receptor that can be detected in the cerebrospinal fluid.
The data obtained show a decrease in the incidence and a slight increase in mortality from endometrial cancer. The study was conducted by the Infections and Cancer research group from IDIBELL, ICO, and the Oncology Master Plan.
The presence of a high number of repeats of a specific amino acid in the androgen or testosterone receptor is related to a worse clinical course of COVID-19.
Dr. Xavier Matias-Guiu, head of the gynecological cancer research group at IDIBELL, is the new president of the International Society of Gynecological Pathologists (ISGYP) since this weekend.
A study finds that systematized nursing surveillance through the VIDA system, developed by the Catalan Institute of Health and IDIBELL, can detect and prevent complications, transfers to the ICU, and intra-hospital mortality.
This appointment represents a recognition of her professional life dedicated to hematopoietic stem cell transplantation and cell therapies.
The research group led by Dr. Alessandra Giorgetti, leader of the research group “Biology of Hematopoietic Stem Cells and Leukemogenesis” of IDIBELL, and professor at the UB, has received a grant of € 15,000 from the GESMD (Spanish Group of Myelodysplastic Syndromes), a group of which Giorgetti is an active member.
Work financed by the Territorial Specialization and Competitiveness Project (PECT) “L’Hospitalet, innovative ecosystem in health.”
Since the beginning of the COVID-19 pandemic, the health and scientific communities have made a formidable effort to respond, within their capabilities, to an unprecedented, rapidly evolving global situation of enormous complexity, and with a high harmful potential.
